“For Rhemedi, artificial intelligence is not the final objective,” Rhemedi founder and clinical governance lead Rheza Maulana Syahputra said in a statement.

“AI is a tool to help people understand health more deeply, recognize risks earlier and take more appropriate action, while clinical responsibility remains with physicians and healthcare professionals.”

Rheza said that achieving OpenAI Select Partner status is both an honor and a responsibility for the company to continue developing "medical intelligence" responsibly, with the hope of expanding access to preventive medicine and more effective healthcare, particularly for the people of Indonesia.

The OpenAI Partner Network is a global program for partners to build, sell and deliver AI solutions with OpenAI, widely known as the company behind Chat GPT.

The network brings together partners with deep industry expertise, delivery capabilities and customer relationships while equipping them with resources, enablement and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact.

Prospects

Every Monday

With exclusive interviews and in-depth coverage of the region's most pressing business issues, "Prospects" is the go-to source for staying ahead of the curve in Indonesia's rapidly evolving business landscape.

View More Newsletter

By registering, you agree with The Jakarta Post's Privacy Policy

Sign Up

Thank You

for signing up our newsletter!

Please check your email for your newsletter subscription.

View More Newsletter

Rhemedi will focus on applying these capabilities across healthcare, including preventive medicine, precision diagnostics, imaging and medical intelligence, with a particular focus on supporting responsible AI adoption in healthcare in Indonesia.

As an OpenAI Select Partner, Rhemedi will continue working with OpenAI to help organizations build, deploy and scale AI solutions responsibly and effectively. This work will help organizations put the most sophisticated model, currently the GPT-6 Astra, to work across more of their business, using deeper reasoning and computer use to complete complex workflows and deliver finished work.

One of Rhemedi’s ongoing initiatives is the Rhemedi Medical Intelligence Assistant (RHE-INA), a physician-governed platform being developed to help structure fragmented clinical information, laboratory data, medical documents, imaging and progressively genomic data for governed, auditable review by healthcare professionals.

AI is positioned as a supporting tool; diagnosis, treatment decisions and clinical interventions remain under the authority of qualified healthcare professionals.

An earlier event-specific deployment of RHE-INA was implemented as RHE-NU, a custom-made AI-assisted health companion that supported healthcare services during a large-scale mass-gathering event in Indonesia in August.

This real-world deployment provided operational learning in AI-assisted intake, healthcare navigation, clinical escalation and the integration of technology with medical professionals.

Rhemedi views healthcare as one of the fields where AI has significant potential when developed alongside strong domain expertise and governance. Rhemedi’s areas of focus include preventive medicine, precision diagnostics, imaging and radiology, Medical Intelligence, as well as the long-term development and integration of radiogenomics.

Going forward, Rhemedi will continue to strengthen its technical capabilities, clinical governance, multimodal health-data integration, imaging services that can be deployed safely across different healthcare environments.

Popular

Recentralization concerns in fiscal, education heighten

Indonesia calls for more representative UN amid changing world order

Twenty years on, BRICS faces a defining choice